Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Copflugerix
- Development stage
- Unknown
- Lead developer
- Saniona
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Copflugerix is a small molecule drug candidate currently in Phase 1 clinical development for the treatment of migraine. The program is managed through a joint venture in which Saniona holds a 25% ownership stake. While specific details regarding its biological target and mechanism of action have not been publicly disclosed in Saniona's primary pipeline communications, the drug is part of Saniona's broader portfolio of ion channel-targeting compounds focused on neurological and pain disorders. The development is being conducted in collaboration with unspecified joint venture partners.
- Other names
- Copflugerix Program
Beyond the preview
Go deeper on Copflugerix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Copflugerix.